Acute effects of MDMA (3,4-methylenedioxymethamphetamine) on EEG oscillations: alone and in combination with ethanol or THC (delta-9-tetrahydrocannabinol). 2011

Marieke M Lansbergen, and Glenn J H Dumont, and Joop M A van Gerven, and Jan K Buitelaar, and Robbert-Jan Verkes
Department of Psychiatry, Donders Institute for Brain, Cognition and Behaviour, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands. M.Lansbergen@psy.umcn.nl

BACKGROUND Typical users of 3,4-methylenedioxymethamphetamine (MDMA or "ecstasy") are polydrug users, combining MDMA with alcohol or cannabis [most active compound: delta-9-tetrahydrocannabinol (THC)]. OBJECTIVE The aim of the present study was to investigate whether co-administration of alcohol or THC with MDMA differentially affects ongoing electroencephalogram (EEG) oscillations compared to the administration of each drug alone. METHODS In two separate experiments, 16 volunteers received four different drug conditions: (1) MDMA (100 mg); (2) alcohol clamp (blood alcohol concentration = 0.6‰) or THC (inhalation of 4, 6 and 6 mg, interval of 1.5 h); (3) MDMA in combination with alcohol or THC; and (4) placebo. Before and after drug administration, electroencephalography was recorded during an eyes closed resting state. RESULTS Theta and alpha power increased after alcohol intake compared to placebo and reduced after MDMA intake. No interaction between alcohol and MDMA was found. Significant MDMA x THC effects for theta and lower-1-alpha power indicated that the power attenuation after the combined intake of MDMA and THC was less than the sum of each drug alone. For the lower-2-alpha band, the intake of MDMA or THC alone did not significantly affect power, but the intake of combined MDMA and THC significantly decreased lower-2-alpha power. CONCLUSIONS The present findings indicate that the combined intake of MDMA and THC, but not of MDMA and alcohol, affects ongoing EEG oscillations differently than the sum of either one drug alone. Changes in ongoing EEG oscillations may be related to the impaired task performance that has often been reported after drug intake.

UI MeSH Term Description Entries
D008297 Male Males
D001921 Brain The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM. Encephalon
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D004347 Drug Interactions The action of a drug that may affect the activity, metabolism, or toxicity of another drug. Drug Interaction,Interaction, Drug,Interactions, Drug
D004569 Electroencephalography Recording of electric currents developed in the brain by means of electrodes applied to the scalp, to the surface of the brain, or placed within the substance of the brain. EEG,Electroencephalogram,Electroencephalograms
D005260 Female Females
D006213 Hallucinogens Drugs capable of inducing illusions, hallucinations, delusions, paranoid ideations, and other alterations of mood and thinking. Despite the name, the feature that distinguishes these agents from other classes of drugs is their capacity to induce states of altered perception, thought, and feeling that are not experienced otherwise. Hallucinogen,Hallucinogenic Agent,Hallucinogenic Drug,Hallucinogenic Substance,Psychedelic,Psychedelic Agent,Psychedelic Agents,Psychotomimetic Agent,Psychotomimetic Agents,Hallucinogenic Agents,Hallucinogenic Drugs,Hallucinogenic Substances,Psychedelics,Agent, Hallucinogenic,Agent, Psychedelic,Agent, Psychotomimetic,Agents, Hallucinogenic,Agents, Psychedelic,Agents, Psychotomimetic,Drug, Hallucinogenic,Drugs, Hallucinogenic,Substance, Hallucinogenic,Substances, Hallucinogenic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths

Related Publications

Marieke M Lansbergen, and Glenn J H Dumont, and Joop M A van Gerven, and Jan K Buitelaar, and Robbert-Jan Verkes
May 2006, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology,
Marieke M Lansbergen, and Glenn J H Dumont, and Joop M A van Gerven, and Jan K Buitelaar, and Robbert-Jan Verkes
January 2001, The Journal of pharmacology and experimental therapeutics,
Marieke M Lansbergen, and Glenn J H Dumont, and Joop M A van Gerven, and Jan K Buitelaar, and Robbert-Jan Verkes
July 1991, Pharmacology, biochemistry, and behavior,
Marieke M Lansbergen, and Glenn J H Dumont, and Joop M A van Gerven, and Jan K Buitelaar, and Robbert-Jan Verkes
September 2008, The international journal of neuropsychopharmacology,
Marieke M Lansbergen, and Glenn J H Dumont, and Joop M A van Gerven, and Jan K Buitelaar, and Robbert-Jan Verkes
May 2022, Psychopharmacology,
Marieke M Lansbergen, and Glenn J H Dumont, and Joop M A van Gerven, and Jan K Buitelaar, and Robbert-Jan Verkes
April 2020, Cellular immunology,
Marieke M Lansbergen, and Glenn J H Dumont, and Joop M A van Gerven, and Jan K Buitelaar, and Robbert-Jan Verkes
September 2004, Toxicon : official journal of the International Society on Toxinology,
Marieke M Lansbergen, and Glenn J H Dumont, and Joop M A van Gerven, and Jan K Buitelaar, and Robbert-Jan Verkes
August 1982, Neuropharmacology,
Marieke M Lansbergen, and Glenn J H Dumont, and Joop M A van Gerven, and Jan K Buitelaar, and Robbert-Jan Verkes
March 1971, The Journal of pharmacy and pharmacology,
Marieke M Lansbergen, and Glenn J H Dumont, and Joop M A van Gerven, and Jan K Buitelaar, and Robbert-Jan Verkes
September 1978, Experientia,
Copied contents to your clipboard!